Liberal Versus Restrictive Transfusion Threshold in Oncologic surgerY

Anemia Clinical Trial

— LIBERTY1  

Official title:

Liberal Versus Restrictive Transfusion Threshold in High-risk Oncologic surgerY: a Multicenter, Randomized, Controlled, Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04506125
• Other study ID #: 29BRC20.0086
• Status: Completed
• Phase: N/A
• Start date: March 18, 2021
• Est. completion date: August 29, 2022

Study information

• Verified date: July 2023
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Anemia is common in oncology. Up to three-quarters of cancer patients are exposed to an episode of anemia. In oncology surgery, perioperative bleeding is a major risk factor for anemia. Indeed, 13 to 40% of patients are transfused in perioperative oncologic surgery.

There is an association between anemia and prognosis. Several epidemiological studies have shown a strong association between anemia and altered quality of life. In oncology cohort studies, anemic patients had a significantly lower quality of life compared to patients without anemia. In non-cardiac surgery, preoperative anaemia was significantly associated with post-operative mortality. There is also an association between preoperative anaemia and the occurrence of post-operative complications. In oncology surgery, cohort studies conducted in colorectal surgery and neurosurgery found an association between the occurrence of perioperative anemia and post-operative morbidity and mortality.

The optimal transfusion strategy is unknown in oncology patients. Several multicentre randomised trials, conducted in resuscitation patients or in perioperative settings, have compared a "restrictive" to a "liberal" transfusion strategy. These studies did not show a superiority of one strategy over another on patient outcomes but a lower exposure to red blood cell concentrates in patients transfused with the restrictive transfusion strategy. Thus, the French High Authority for Health (HAS) has adopted a haemoglobin level of 7 g/dl as the transfusion threshold for any transfusion of red blood cell concentrate carried out in the operating theatre and in intensive care in the absence of special cases such as the presence of acute coronary syndrome. For oncology patients, no recommendation could be made due to the lack of evidence-based literature and the optimal transfusion strategy for these patients remains unknown. Only 2 monocentric trials performed in oncology (critical care and perioperative) suggest a benefit of a liberal strategy (transfusion for a haemoglobin level < 9 g/dl) on the short-term vital prognosis, but these studies suffer from numerous limitations leaving the question unresolved.

Before conducting a large phase III trial, a pilot study is needed to validate the methodology of this multicentre clinical trial and to assess its feasibility.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 29, 2022
• Est. primary completion date: August 29, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years old

• Anticipated or proven admission to immediate postoperative resuscitation after scheduled or emergency oncology surgery, for the removal of a neoplastic lesion among the following surgical procedures:

• Visceral surgery: Hepatectomy, duodenopancreatectomy, gastrectomy, esophagectomy, colectomy

• Urological surgery: Radical prostatectomy, cystectomy, nephrectomy.

• Gynaecological surgery: Ovariectomy, hysterectomy, mastectomy, pelvectomy

• Thoracic surgery: Pneumonectomy, lobectomy

• ENT Surgery: Total laryngectomy, pharyngectomy, glossectomy

• Spinal surgery: corporectomy wherever it is performed.

• Hemoglobin level < 9.5 g/dl between the day before surgery (D-1) and discharge from resuscitation at no more than 30 days postoperatively

Exclusion Criteria:

• - Myocardial infarction and/or unstable angina in the 4 weeks prior to surgery

• Refusal to participate in the study

• Minor patient (age < 18 years)

• Refusal to transfuse red blood cell concentrates (Jehovah's Witness)

• Pregnant or breastfeeding women

• Patients under guardianship or curatorship

Related Conditions & MeSH terms

• Anemia
• Oncologic Complications

Intervention

Other:
• Haemoglobin 9.5 g/dL
transfusion of red blood cell concentrate if the haemoglobin level is less than 9,5 g/dL
• Haemoglobine 7.5g/dL
transfusion of red blood cell concentrate if the haemoglobin level is less than 7,5 g/dL

Locations

Country	Name	City	State
France	CHU d'Angers	Angers
France	CHRU de Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Methodology of the pilot study	The difference in mean hemoglobin levels during the perioperative period up to 30 days postoperatively between the two groups will be assessed	up to 30 days
Secondary	Epidemiological data of the pilot study	The percentage of patients with oncologic surgery admitted to intensive care unit requiring transfusion of red blood cell concentrates eerioperatively among aatients with oncologic surgery admitted to intensive care unit will be assessed	up to 90 days
Secondary	Epidemiological data of the pilot study	Percentage of eligible patients included in the study will be assessed	up to 90 days
Secondary	Epidemiological data of the pilot study	Delay between surgery and randomization will be assessed	up to 90 days
Secondary	Epidemiological data of the pilot study	Percentage of protocol violations in each group will be assessed	up to 90 days
Secondary	Epidemiological data of the pilot study	Average number of erythrocyte concentrates delivered to each group intraoperatively, in intensive care and during hospitalization will be assessed	up to 90 days
Secondary	Epidemiological data of the pilot study	Post-operative complications, occurring between surgery and the 30th day after surgery or before discharge from hospital will be assessed	up to 90 days
Secondary	Adverse Reaction Monitoring	To compare the occurrence of transfusion-related adverse events in each group	up to 30 days
Secondary	Evaluation of the functional status	Test functional status assessment at 30 days postoperatively using the World Health Organization Disability Assessment Schedule (WHODAS) questionnaire.; This questionnaire asks about difficulties due to health/mental health conditions. Health conditions include diseases or illnesses, other health problems that may be short or long lasting, injuries, mental or emotional problems, and problems with alcohol or drugs. The patient must think back over the past 30 days and answer the questions thinking about how much difficulty you had doing the following activities.	up to 30 days
Secondary	Evaluation of the functional status after surgery ans anesthesia	Test functional status assessment at 30 days postoperatively using the Quality of recovery questionnaire.; The Quality of Recovery-15 (QoR-15) is a psychometrically tested and validated questionnaire.; The QoR-15 was psychometrically evaluated using data collected from patients who responded at all four time intervals.This included: Acceptability and Feasibility; Validity; Reliability; Responsiveness	up to 30 days
Secondary	Monitoring of the quality of the study's execution	Compare the percentage of protocol violations in the 2 groups	up to 30 days